Clinical Trials
9 trialsNCT07484022 2026-05-15
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Generate Biomedicines
Phase 1 Recruiting
NCT04865679 2025-05-02
REPOSE-XLâ„
Axogen Corporation
Phase NA Active not recruiting
NCT05488873 2024-07-22
A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy
WinSanTor, Inc
Phase 2 Active not recruiting
NCT04675450 2023-06-08
NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
Conjupro Biotherapeutics, Inc.
Phase 2 Withdrawn
NCT04034355 2022-01-26
POLAR-A
Egetis Therapeutics
Phase 3 Terminated
NCT00751205 2014-10-28
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
Bayer
Phase 2 Completed
NCT00267007 2014-06-04
A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Terminated
NCT00380965 2008-02-15
Evaluation of the Efficacy of Cesametâ„¢ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy
NEMA Research, Inc.
Phase 4 Completed
NCT00041795 2005-06-24
Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy
NeoTherapeutics
Phase 2 Completed